# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number

# B Applicant

Horiba ABX SAS

# C Proprietary and Established Names

Yumizen C1200 Immunoglobulin A, Yumizen C1200 Immunoglobulin G, Yumizen C1200 Immunoglobulin M

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CZP</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5510 - Immunoglobulins A, G, M, D, And EImmunological Test System</td><td rowspan=1 colspan=1>IM -Immunology</td></tr><tr><td rowspan=1 colspan=1>DEW</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 866.5510 - Immunoglobulins A, G, M, D, and Eimmunological test system</td><td rowspan=1 colspan=1>IM -Immunology</td></tr><tr><td rowspan=1 colspan=1>CFN</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5510 - Immunoglobulins A, G, M, D, and Eimmunological test system</td><td rowspan=1 colspan=1>IM-Immunology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission: New Assays

# B Measurand:

Immunoglobulin A (IgA) Immunoglobulin G (IgG) Immunoglobulin M (IgM)

# C Type of Test:

Quantitative immunoturbidimetric assays

# III Intended Use/Indications for Use:

# A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

Yumizen C1200 Immunoglobulin A reagent is intended for the quantitative in vitro diagnostic determination of Immunoglobulin A (IgA) in serum and lithium heparin plasma by immunoturbidimetry on Yumizen analyzers. Measurement of this immunoglobulin aids in the diagnosis of abnormal protein metabolism and the body’s lack of ability to resist infectious agents. This test should be used in conjunction with other laboratory and clinical findings.

Yumizen C1200 Immunoglobulin G reagent is intended for the quantitative in vitro diagnostic determination of Immunoglobulin G (IgG) in serum and lithium heparin plasma by immunoturbidimetry on Yumizen analyzers. Measurement of this immunoglobulin aids in the diagnosis of abnormal protein metabolism and the body’s lack of ability to resist infectious agents. This test should be used in conjunction with other laboratory and clinical findings.

Yumizen C1200 Immunoglobulin M reagent is intended for the quantitative in vitro diagnostic determination of Immunoglobulin M (IgM) in serum and lithium heparin plasma by immunoturbidimetry on Yumizen analyzers. Measurement of this immunoglobulin aids in the diagnosis of abnormal protein metabolism and the body’s lack of ability to resist infectious agents. This test should be used in conjunction with other laboratory and clinical findings.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

# D Special Instrument Requirements:

For the Yumizen C1200 (K183375 and K191993) only

# IV Device/System Characteristics:

# A Device Description:

Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { A }$ : • Reagent 1: TRIS buffer solution ′ Reagent 2: Goat anti-human IgA antibodies in TRIS buffer

Yumizen C1200 IgG:

• Reagent 1: TRIS buffer solution Reagent 2: Goat anti-human IgG antibodies in TRIS buffer

Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { M }$ :

Reagent 1: TRIS buffer solution Reagent 2: Goat anti-human IgM antibodies in TRIS buffer

All assays’ calibrators and control materials are sold separately.

# B Principle of Operation:

These immunoturbidimetric assays measure increasing sample turbidity caused by the formation of insoluble immune complexes when goat anti-human immunoglobulin (IgA, IgG, or IgM) antibodies are bound to the specific immunoglobulin (IgA, IgG, or IgM) in the sample. The IgA, IgG, or IgM concentration is proportional to the amount of turbidity formed.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Olympus IgA Reagent, Olympus IgG Reagent, Olympus IgM Reagent   
B Predicate 510(k) Number(s): K073489, K073490, K073487

# C Comparison with Predicate(s):

Yumizen C1200 IgA:

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K193525</td><td colspan="1" rowspan="1">K073489</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Yumizen C1200 IgA</td><td colspan="1" rowspan="1">Olympus IgA Reagent,Model: OSR6X171</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications For Use</td><td colspan="1" rowspan="1">Yumizen C1200 ImmunoglobulinA reagent is intended for thequantitative in vitro diagnosticdetermination ofImmunoglobulin A (IgA) inserum and lithium heparinplasma by immunoturbidimetryon Yumizen analyzers.Measurement of thisimmunoglobulin aids in the</td><td colspan="1" rowspan="1">System reagent for thequantitative determination ofIgA immunoglobulins inhuman serum and plasma onBeckman Coulter AUanalyzers.The spectrum ofabnormalities in serumimmunoglobulinconcentrations is broad.</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">diagnosis of abnormal proteinmetabolism and the body's lackof ability to resist infectiousagents. This test should be usedin conjunction with otherlaboratory and clinical findings.</td><td colspan="1" rowspan="1">Abnormal concentrationsrange from a virtual absenceof one or more of the threemajor classes ofimmunoglobulin (IgG, IgA,and IgM) to polyclonalincreases in one or moreimmunoglobulins.Measurement of theseimmunoglobulins aids in thediagnosis of abnormalprotein metabolism and thebody's lack of ability toresist infectious agents.For in vitro diagnostic use.</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">10700 mg/dL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">DA470k/IFCC</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument Platform</td><td colspan="1" rowspan="1">Yumizen C1200</td><td colspan="1" rowspan="1">Beckman CoulterOlympus AU400</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Immunoturbidimetry</td><td colspan="1" rowspan="1">Turbidimetry</td></tr><tr><td colspan="1" rowspan="1">Sample Matrices</td><td colspan="1" rowspan="1">SerumLi-heparin plasma</td><td colspan="1" rowspan="1">SerumLi-heparin plasmaEDTA plasma</td></tr><tr><td colspan="1" rowspan="1">On-board reagent stability</td><td colspan="1" rowspan="1">60 days</td><td colspan="1" rowspan="1">6 weeks</td></tr><tr><td colspan="1" rowspan="1">Reference range</td><td colspan="1" rowspan="1">70-400 mg/dL</td><td colspan="1" rowspan="1">66433 mg/dL</td></tr></table>

# Yumizen C1200 IgG:

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K193525</td><td colspan="1" rowspan="1">K073490</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Yumizen C1200 IgG</td><td colspan="1" rowspan="1">Olympus IgG Reagent,Model: OSR6X172</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications For Use</td><td colspan="1" rowspan="1">Yumizen C1200 ImmunoglobulinG reagent is intended for thequantitative in vitro diagnosticdetermination ofImmunoglobulin G (IgG) in</td><td colspan="1" rowspan="1">System reagent for thequantitative determinationof IgG immunoglobulins inhuman serum and plasmaon Beckman Coulter AU</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">serum and lithium heparinplasma by immunoturbidimetryon Yumizen analyzers.Measurement of thisimmunoglobulin aids in thediagnosis of abnormal proteinmetabolism and the body's lackof ability to resist infectiousagents. This test should be usedin conjunction with otherlaboratory and clinical findings.</td><td colspan="1" rowspan="1">analyzers.The measurement of IgGaids in the diagnosis ofabnormal proteinmetabolism and the body'slack of ability to resistinfectious agents.For in vitro diagnostic use.</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">753000 mg/dL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">DA470k/IFCC</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument Platform</td><td colspan="1" rowspan="1">Yumizen C1200</td><td colspan="1" rowspan="1">Beckman CoulterOlympus AU400</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Immunoturbidimetry</td><td colspan="1" rowspan="1">Turbidimetry</td></tr><tr><td colspan="1" rowspan="1">Sample Matrices</td><td colspan="1" rowspan="1">SerumLi-heparin plasma</td><td colspan="1" rowspan="1">SerumLi-heparin plasmaEDTA plasma</td></tr><tr><td colspan="1" rowspan="1">On-board reagent stability</td><td colspan="1" rowspan="1">6 weeks</td><td colspan="1" rowspan="1">90 days</td></tr><tr><td colspan="1" rowspan="1">Reference range</td><td colspan="1" rowspan="1">7001600 mg/dL</td><td colspan="1" rowspan="1">6351741 mg/dL</td></tr></table>

# Yumizen C1200 IgM:

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K193525</td><td colspan="1" rowspan="1">K073487</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">Yumizen C1200 IgM</td><td colspan="1" rowspan="1">Olympus IgM Reagent,Model: OSR6X173</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications For Use</td><td colspan="1" rowspan="1">Yumizen C1200 ImmunoglobulinM reagent is intended for thequantitative in vitro diagnosticdetermination of ImmunoglobulinM (IgM) in serum and lithiumheparin plasma byimmunoturbidimetry on Yumizenanalyzers. Measurement of thisimmunoglobulin aids in thediagnosis of abnormal proteinmetabolism and the body's lack of</td><td colspan="1" rowspan="1">System reagent for thequantitative determinationof IgM immunoglobulinsin human serum andplasma on BeckmanCoulter AU analyzers.The spectrum ofabnormalities in serumimmunoglobulinconcentrations is broad.Abnormal concentrations</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ability to resist infectious agents.This test should be used inconjunction with other laboratoryand clinical findings.</td><td colspan="1" rowspan="1">range from a virtualabsence of one or more ofthe three major classes ofimmunoglobulin (IgA,IgG, and IgM) topolyclonal increases inone or moreimmunoglobulins.Measurement of theseimmunoglobulins aids inthe diagnosis of abnormalprotein metabolism andthe body's lack of abilityto resist infectious agents.For in vitro diagnosticuse.</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">20500 mg/dL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reagent Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability/Standardization</td><td colspan="1" rowspan="1">DA470k/IFCC</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument Platform</td><td colspan="1" rowspan="1">Yumizen C1200</td><td colspan="1" rowspan="1">Beckman CoulterOlympus AU400</td></tr><tr><td colspan="1" rowspan="1">Assay Method</td><td colspan="1" rowspan="1">Immunoturbidimetry</td><td colspan="1" rowspan="1">Turbidimetry</td></tr><tr><td colspan="1" rowspan="1">Sample Matrices</td><td colspan="1" rowspan="1">SerumLi-heparin plasma</td><td colspan="1" rowspan="1">SerumLi-heparin plasmaEDTA plasma</td></tr><tr><td colspan="1" rowspan="1">On-board reagent stability</td><td colspan="1" rowspan="1">6 weeks</td><td colspan="1" rowspan="1">90 days</td></tr><tr><td colspan="1" rowspan="1">Reference range</td><td colspan="1" rowspan="1">40230 mg/dL</td><td colspan="1" rowspan="1">45281 mg/dL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

• CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures– Third Edition - October 2014   
• CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures – Second Edition - June 2012   
• CLSI EP06-A: Evaluation of the Linearity of Quantitative measurement Procedures A Statistical Approach – First Edition – April 2003   
• CLSI C28-A3: Defining, Establishing, and Verifying Reference Intervals in the Clinical laboratory- Third Edition – November 2008 CLSI EP25-A: Evaluation of Stability of In Vitro Diagnostic reagents- First EditionSeptember 2009

# VII Performance Characteristics (if/when applicable):

A Analytical Performance:

# 1. Precision/Reproducibility:

Yumizen C1200 IgA:

The precision of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { A }$ assay was evaluated on three Yumizen C1200 immunoassay analyzers using one reagent lot. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested with two replicates per run, two runs per day for 20 days on each analyzer $\scriptstyle ( 1 = 2 4 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2>IgA</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>239</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>431</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>14.2</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>16.7</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>547</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>15.8</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>365</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>3.1</td></tr></table>

The lot-to-lot reproducibility of the Yumizen $\mathrm { C 1 2 0 0 \mathrm { I g { A } } }$ assay was evaluated on one analyzer using three reagent lots. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested in triplicates per run, two runs per day for five days on each lot $\mathrm { \Pi } _ { \mathrm { n } } { = } 9 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2>IgA</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Lot</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>113</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>434</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>563</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>372</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.1</td></tr></table>

# Yumizen C1200 IgG:

The precision of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g G }$ assay was evaluated on three Yumizen C1200 immunoassay analyzers using one reagent lot. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested with two replicates per run, two runs per day for 20 days on each analyzer $( \mathrm { n } { = } 2 4 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2>IgG</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>314</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>541</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>1027</td><td rowspan=1 colspan=1>15.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>25.7</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>1721</td><td rowspan=1 colspan=1>29.8</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>24.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>41.6</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>2236</td><td rowspan=1 colspan=1>46.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>39.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>25.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>15.8</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>659</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>19.0</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>1885</td><td rowspan=1 colspan=1>34.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>43.7</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>26.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>62.4</td><td rowspan=1 colspan=1>3.3</td></tr></table>

The lot-to-lot reproducibility of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g G }$ assay was evaluated on one analyzer using three reagent lots. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested in triplicates per run, two runs per day for five days on each lot $\mathrm { \Pi } _ { \mathrm { n } } { = } 9 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2>IgG</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Lot</td><td rowspan=1 colspan=2>Between-Lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>306</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>530</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>994</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>12.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>16.0</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>1666</td><td rowspan=1 colspan=1>21.1</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>17.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>27.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>17.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>32.7</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>2184</td><td rowspan=1 colspan=1>23.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>18.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>30.0</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>31.5</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>636</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>10.1</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>1821</td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>23.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>33.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>33.9</td><td rowspan=1 colspan=1>1.9</td></tr></table>

# Yumizen C1200 IgM:

The precision of the Yumizen $\mathrm { C 1 2 0 0 \mathrm { I g } M }$ assay was evaluated on three Yumizen C1200 immunoassay analyzers using one reagent lot. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested with two replicates per run, two runs per day for 20 days on each analyzer $( \mathrm { n } { = } 2 4 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2>IgM</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Instrument</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>161</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>443</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>273</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>1.8</td></tr></table>

The lot-to-lot reproducibility of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { M }$ assay was evaluated on one analyzer using three reagent lots. Five human sera samples and two levels of Yumizen C1200 Protein Control were tested in triplicates per run, two runs per day for five days on each lot $( \mathtt { n } \mathtt { = } 9 0$ per sample). The results are summarized below:

<table><tr><td rowspan=1 colspan=2>IgM</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>Within Lot</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Sera 1</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>Sera 2</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>Sera 3</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Sera 4</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Sera 5</td><td rowspan=1 colspan=1>444</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>276</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>1.7</td></tr></table>

2. Linearity:

Yumizen C1200 IgA:

Linearity: Linearity of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { A }$ assay was assessed according to CLSI EP06-A. A high concentration IgA-spiked human serum sample and an IgA-depleted serum were used to create a dilution series covering above and below the measuring range. Sample dilutions were assayed in quadruplicate within a single run and samples within the measuring range were used to determine linearity:

<table><tr><td rowspan=1 colspan=1>Dilution Range(mg/dL)</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>21-660</td><td rowspan=1 colspan=1>y=1.027x-0.004</td><td rowspan=1 colspan=1>1.0121.043</td><td rowspan=1 colspan=1>-0.0600.051</td><td rowspan=1 colspan=1>0.998</td></tr></table>

Auto-rerun validation study: An auto-rerun study was performed to evaluate the accuracy of the analyzer’s auto dilution function to obtain results for $\mathrm { I g A }$ samples with analyte concentrations above the primary measuring range $( 7 0 0 \mathrm { m g / d L } )$ . Seven samples were used for the study, ranging from $7 1 5 { - } 1 9 8 8 \ \mathrm { m g / d L }$ . Each sample was manually diluted with a 1:3 ratio. The automatic instrument dilutions and the manual dilutions were measured in quadruplicates. The results of the auto-rerun study support the claim that samples having concentrations up to $2 1 0 0 \mathrm { m g / d L }$ can be run via the rerun function which uses a 1:3 dilution.

Prozone effect: The potential for a prozone effect was evaluated for the IgA assay. Testing elevated samples did not indicate a prozone effect with concentrations up to 2320 mg/dL.

Linearity: Linearity of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { G }$ assay was assessed according to CLSI EP06-A. A high concentration IgG-spiked human serum sample and an IgG-depleted serum were used to create a dilution series covering above and below the measuring range. Sample dilutions were assayed in quadruplicate within a single run and samples within the measuring range were used to determine linearity:

<table><tr><td rowspan=1 colspan=1>Dilution Range(mg/dL)</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>R²</td></tr><tr><td rowspan=1 colspan=1>822942</td><td rowspan=1 colspan=1>y=0.996x-0.254</td><td rowspan=1 colspan=1>0.9851.008</td><td rowspan=1 colspan=1>0.070- -0.440</td><td rowspan=1 colspan=1>0.999</td></tr></table>

Auto-rerun validation study: An auto-rerun study was performed to evaluate the accuracy of the analyzer’s auto dilution function to obtain results for $\mathrm { I g G }$ samples with analyte concentrations above the primary measuring range ( $3 0 0 0 \mathrm { m g / d L } )$ . Seven samples were used for the study, ranging from $3 1 2 0 { - } 8 7 3 8 ~ \mathrm { m g / d L }$ . Each sample was manually diluted with a 1:3 ratio. The automatic instrument dilutions and the manual dilutions were measured in quadruplicates. The results of the auto-rerun study support the claim that samples having concentrations up to $9 0 0 0 \mathrm { m g / d L }$ can be run via the rerun function which uses a 1:3 dilution.

Prozone effect: The potential for a prozone effect was evaluated for the IgG assay. Testing elevated samples did not indicate a prozone effect with concentrations up to 9860 mg/dL.

# Yumizen C1200 IgM:

Linearity: Linearity of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { M }$ assay was assessed according to CLSI EP06-A. A high concentration IgM-spiked human serum sample and an IgM-depleted serum were used to create a dilution series covering above and below the measuring range. Sample dilutions were assayed in quadruplicate within a single run and samples within the measuring range were used to determine linearity:

<table><tr><td rowspan=1 colspan=1>Dilution Range(mg/dL)</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>R²</td></tr><tr><td rowspan=1 colspan=1>26416</td><td rowspan=1 colspan=1>y=1.013x-0.087</td><td rowspan=1 colspan=1>1.001-1.025</td><td rowspan=1 colspan=1>-0.115- -0.059</td><td rowspan=1 colspan=1>0.998</td></tr></table>

Auto-rerun validation study: An auto-rerun study was performed to evaluate the accuracy of the analyzer’s auto dilution function to obtain results for $\mathrm { I g M }$ samples with analyte concentrations above the primary measuring range $( 5 0 0 \mathrm { m g / d L } )$ . Seven samples were used for the study, ranging from $5 5 7 \mathrm { - } 1 3 6 1 ~ \mathrm { m g / d L }$ . Each sample was manually diluted with a 1:3 ratio. The automatic instrument dilutions and the manual dilutions were measured in quadruplicates. The results of the auto-rerun study support the claim that samples having concentrations up to $1 5 0 0 \mathrm { m g / d L }$ can be run via the rerun function which uses a 1:3 dilution.

Prozone effect: The potential for a prozone effect was evaluated for the IgM assay. Testing elevated samples did not indicate a prozone effect with concentrations up to 5000 mg/dL.

# 3. Analytical Specificity/Interference:

For all three assays, the effect of the presence of endogenous and exogenous interferents in samples was evaluated by testing native unmodified serum pools at two analyte levels (normal and high) with a range of concentrations of the substances listed below. Each sample was tested at four concentrations of interferent and with an interferent-free control in four replicates each. The percent recovery for each sample spiked with the interference substance was calculated by comparing its result to that of the corresponding reference sample spiked with an equal volume of the solvent without the interference substance. No interference was observed up to the following concentration of each interference substance for each assay.

<table><tr><td rowspan=1 colspan=1>Interferent (mg/dL)</td><td rowspan=1 colspan=1>IgA</td><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>IgM</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500.0</td><td rowspan=1 colspan=1>500.0</td><td rowspan=1 colspan=1>250.0</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>531.1</td><td rowspan=1 colspan=1>456.8</td><td rowspan=1 colspan=1>520.6</td></tr><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>29.2</td><td rowspan=1 colspan=1>39.0</td><td rowspan=1 colspan=1>27.9</td></tr><tr><td rowspan=1 colspan=1>Direct Bilirubin</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>18.4</td><td rowspan=1 colspan=1>13.1</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>65.2</td><td rowspan=1 colspan=1>65.2</td><td rowspan=1 colspan=1>65.2</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50.1</td><td rowspan=1 colspan=1>50.1</td><td rowspan=1 colspan=1>50.1</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>20.0</td></tr></table>

4. Assay Reportable Range: Yumizen C1200 IgA: The claimed measuring range is from $1 0 \mathrm { m g / d L }$ to $7 0 0 \mathrm { m g / d L }$ . Yumizen C1200 IgG: The claimed measuring range is from $7 5 \mathrm { m g / d L }$ to $3 0 0 0 \mathrm { m g / d L }$ . Yumizen C1200 IgM: The claimed measuring range is from $2 0 \mathrm { m g / d L }$ to $5 0 0 \mathrm { m g / d L }$ .

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Traceability: All three assays are traceable to ERM-DA470k/IFCC.

Stability:

Real-time shelf-life stability testing supports a shelf-life for unopened reagents stored at the labeling recommendation $( 2 \mathrm { - } 8 ^ { \circ } \mathrm { C } )$ . On-board reagent stability studies support the claims that the reagents can be stored on board the Yumizen C1200. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Stability Claims</td><td rowspan=1 colspan=1>IgA</td><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>IgM</td></tr><tr><td rowspan=1 colspan=1>Reagent Shelf-lifeif stored as recommended</td><td rowspan=1 colspan=1>24 months</td><td rowspan=1 colspan=1>24 months</td><td rowspan=1 colspan=1>24 months</td></tr><tr><td rowspan=1 colspan=1>Reagent On-board</td><td rowspan=1 colspan=1>6 weeks</td><td rowspan=1 colspan=1>6 weeks</td><td rowspan=1 colspan=1>6 weeks</td></tr><tr><td rowspan=1 colspan=1>Serum Sample*</td><td rowspan=1 colspan=1>8 months at 2025°C8 months at 28°C8 months at-20°C</td><td rowspan=1 colspan=1>1 week at 2025°C3 months at 48°&gt;6 months at -20°</td><td rowspan=1 colspan=1>2 months at 2025°C4 months at 48°C6 months at -20°</td></tr><tr><td rowspan=1 colspan=4>*Sample stability claims in the package insert cite published references. The package labelingstates a sample should be frozen only once.</td></tr></table>

# 6. Detection Limit:

The detection limits of all three assays were performed according to CLSI EP17-A2. The Limit of Blank (LoB) corresponds to the concentration below which analyte-free samples are found with a probability of $9 5 \%$ . The Limit of Detection (LoD) is determined based on the limit of blank and the standard deviation of low concentration samples. The limit of detection corresponds to the lowest analyte concentration which can be detected (value above the limit of blank with a probability of $9 5 \%$ ). The Limit of Quantitation (LoQ) was defined as the lowest analyte concentration which can be quantified with a total error of $\leq 2 0 \%$ .

# Yumizen C1200 IgA:

LoB:

The LoB of the IgA assay was determined by assaying one IgA-depleted sample in five replicates per day for four days on three Yumizen instruments. A total of 60 data points per lot were generated; two lots were tested. The LoB for each lot was calculated separately. The LoB was defined as the higher value, $0 . 5 \mathrm { m g / d L }$ .

LoD:

The LoD of the IgA assay was determined by testing four low analyte samples in quadruplicate for four days on one instrument. A total of 64 data points per lot were generated; two lots were tested. The LoD for each lot was calculated separately. The LoD was defined as the higher value, $0 . 9 \mathrm { m g / d L }$ .

The LoQ of the IgA assay was determined by testing five low native samples in quadruplicate per run, two runs per day, for five days on one instrument. A total of 360 data points per lot were generated; two lots were tested. The LoQ for each lot was calculated separately. The LoQ was defined as the higher value, $8 ~ \mathrm { m g / d L }$ .

# Yumizen C1200 IgG:

LoB:

The LoB of the IgG assay was determined by assaying one IgG-depleted sample in five replicates per day for four days on three Yumizen instruments. A total of 60 data points per lot were generated; two lots were tested. The LoB for each lot was calculated separately. The LoB was defined as the higher value, $0 \mathrm { m g / d L }$ .

LoD:

The LoD of the IgG assay was determined by testing four low analyte samples in quadruplicate for four days on one instrument. A total of 64 data points per lot were generated; two lots were tested. The LoD for each lot was calculated separately. The LoD was defined as the higher value, $1 \mathrm { m g / d L }$ .

The LoQ of the IgG assay was determined by testing five low native samples in quadruplicate per run, two runs per day, for five days on one instrument. A total of 360 data points per lot were generated; two lots were tested. The LoQ for each lot was calculated separately. The LoQ was defined as the higher value, $5 3 \mathrm { m g / d L }$ .

# Yumizen C1200 IgM:

The LoB of the IgM assay was determined by assaying one IgM-depleted sample in five replicates per day for four days on three Yumizen instruments. A total of 60 data points per lot were generated; two lots were tested. The LoB for each lot was calculated separately. The LoB was defined as the higher value, $0 . 3 \mathrm { m g / d L }$ .

LoD:

The LoD of the IgM assay was determined by testing four low analyte samples in quadruplicate for four days on one instrument. A total of 64 data points per lot were generated; two lots were tested. The LoD for each lot was calculated separately. The LoD was defined as the higher value, $1 \mathrm { m g / d L }$ .

The LoQ of the IgM assay was determined by testing five low native samples in quadruplicate per run, two runs per day, for five days on one instrument. A total of 360 data points per lot were generated; two lots were tested. The LoQ for each lot was calculated separately. The LoQ was defined as the higher value, $3 \mathrm { m g / d L }$ .

# 7. Assay Cut-Off:

Not applicable.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

# Yumizen C1200 IgA:

The method comparison of the Yumizen $\mathrm { C 1 2 0 0 \mathrm { I g { A } } }$ (candidate device) assay and the predicate device was evaluated. A total of 129 remnant serum samples collected from blood bank covering the measuring range were tested and compared using the Passing-Bablok method. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>11684 mg/dL (Predicate, X)10691 mg/dL (Assay, Y)</td></tr><tr><td rowspan=1 colspan=1>Slope (95th CI)</td><td rowspan=1 colspan=1>0.9941(0.9761.008)</td></tr><tr><td rowspan=1 colspan=1>Intercept (95th CI)</td><td rowspan=1 colspan=1>0.024 (0.0010.052)</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.997</td></tr></table>

# Yumizen C1200 IgG:

The method comparison of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g G }$ (candidate device) assay and the predicate device was evaluated. A total of 214 remnant serum samples collected from a blood bank covering the measuring range were tested and compared using the PassingBablok method. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>772979 mg/dL (Predicate, X)962894 mg/dL (Assay, Y)</td></tr><tr><td rowspan=1 colspan=1>Slope (95th CI)</td><td rowspan=1 colspan=1>1.016 (1.0001.033)</td></tr><tr><td rowspan=1 colspan=1>Intercept (95th CI)</td><td rowspan=1 colspan=1>-0.163 (-0.364-0.030)</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.996</td></tr></table>

# Yumizen C1200 IgM:

The method comparison of the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { M }$ (candidate device) assay and the predicate device was evaluated. A total of 153 remnant serum samples collected from a blood bank covering the measuring range were tested and compared using the PassingBablok method. The results are summarized below:

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>28448 mg/dL (Predicate, X)25441 mg/dL (Assay, Y)</td></tr><tr><td rowspan=1 colspan=1>Slope (95th CI)</td><td rowspan=1 colspan=1>1.005 (0.9931.026)</td></tr><tr><td rowspan=1 colspan=1>Intercept (95th CI)</td><td rowspan=1 colspan=1>0.005 (-0.0150.020)</td></tr><tr><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>0.997</td></tr></table>

2. Matrix Comparison: Serum and lithium heparin are indicated for all three assays.

For the Yumizen $\mathrm { C l } 2 0 0 \mathrm { I g } \mathrm { A }$ assay, a study comparing 62 paired serum and lithium heparin plasma samples demonstrated equivalence between the matrices:

<table><tr><td rowspan=1 colspan=1>Passing-Bablok Fit</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/dL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>Pearson r</td></tr><tr><td rowspan=1 colspan=1>Li-heparin vs. Serum</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>23646</td><td rowspan=1 colspan=1>0.97(0.950.99)</td><td rowspan=1 colspan=1>-0.07(-0.11--0.04)</td><td rowspan=1 colspan=1>0.997</td></tr></table>

Yumizen C1200 IgG:   
For the Yumizen C1200 IgG assay, a study comparing 52 paired serum and lithium heparin   
plasma samples demonstrated equivalence between the matrices:

<table><tr><td rowspan=1 colspan=1>Passing-Bablok Fit</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/dL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>Pearson r</td></tr><tr><td rowspan=1 colspan=1>Li-heparin vs. Serum</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>2052718</td><td rowspan=1 colspan=1>1.12(1.08-1.15)</td><td rowspan=1 colspan=1>-0.84(-1.28--0.48)</td><td rowspan=1 colspan=1>0.994</td></tr></table>

# Yumizen C1200 IgM:

For the Yumizen C1200 IgM assay, a study comparing 44 paired serum and lithium heparin plasma samples demonstrated equivalence between the matrices:

<table><tr><td rowspan=1 colspan=1>Passing-Bablok Fit</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/dL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td><td rowspan=1 colspan=1>Pearson r</td></tr><tr><td rowspan=1 colspan=1>Li-heparin vs. Serum</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>40454</td><td rowspan=1 colspan=1>1.04(1.02-1.06)</td><td rowspan=1 colspan=1>0(-0.02- 0.01)</td><td rowspan=1 colspan=1>0.998</td></tr></table>

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

# D Clinical Cut-Off:

Not applicable.

# E Expected Values/Reference Range:

Yumizen C1200 IgA:

The IgA reference range cited in a reference1 was verified. Samples $\mathrm { \Delta } \cdot \mathrm { \ n } { = } 5 8$ , 22 female and 36 males) from a blood bank were used and the results validate a reference range of $7 0 { \ - } 4 0 0 ~ \mathrm { m g / d L }$

# Yumizen C1200 IgG:

The IgG reference range cited in a reference1 was verified. Samples $\scriptstyle \mathtt { n } = 4 4$ , 16 female and 28 males) from a blood bank were used and the results validate a reference range of 700–1600 mg/dL.

# Yumizen C1200 IgM:

The IgM reference ranges cited in a reference1 was verified. Samples $\mathrm { \Delta } _ { \mathrm { n } } { = } 7 4$ , 29 female and 45 males) from a blood bank were used and the results validate a reference range of $4 0 { - } 2 3 0 \mathrm { m g / d L }$

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.